Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06462222
PHASE1/PHASE2

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Sponsor: Guangzhou Medical University

View on ClinicalTrials.gov

Summary

This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.

Official title: Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors: a Phase I/II Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2024-06-30

Completion Date

2026-07-31

Last Updated

2026-05-11

Healthy Volunteers

No

Interventions

DRUG

Toripalimab, pemetrexed

Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy

Locations (4)

The Affiliated Huizhou Hospital, Guangzhou Medical University

Huizhou, Guangdong, China

Huizhou First Hospital Affiliated to Guangdong Medical University

Huizhou, Guangdong, China

Beijing Chest Hospital, Capital Medical University

Beijing, China

Cancer Center, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine

Beijing, China